Entero Healthcare Solutions Limited has informed the Exchange about Transcript of the Earnings call held on May 28, 2025 to discuss the Company's financial results for the quarter and year ended March 31, 2025
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare reported FY25 revenue of Rs. 5,096 crores, up 30% year-on-year, with 16% organic growth versus industry (IPM) growth of 8%, outpacing the market by 2x. EBITDA rose 53% to Rs. 172 crores with margins expanding 52 basis points to 3.4% (3.7% in the last two quarters). Profit after tax nearly tripled to Rs. 107 crores, and ROCE improved to 11.6% from 9%. The company completed 10 acquisitions adding Rs. 792 crores in annualized revenue, and announced 6 more deals worth over Rs. 400 crores. For FY26, management guided for 30%+ revenue growth, EBITDA margins above 4% on a full-year basis, full-year operating cash flow positivity, and a working capital cycle of 60 days. Management indicated a medium-term EBITDA margin target of around 5% and long-term ROE of 15-20%.
Strong FY25 results, with consistent margin expansion and 2.7x PAT growth, support the growth story. The FY26 guidance of 30%+ revenue growth, >4% EBITDA margins, and full-year OCF positivity should be positive for the stock, though management acknowledged missing the earlier 35-40% growth guidance by about 4% due to acquisition timing delays. Continued outperformance versus a slowing pharma distribution industry (IPM growth at 8%) reinforces the company's competitive positioning.